Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.

Abstract excerpt

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated alcohol‑related liver disease (MetALD) are increasingly recognized conditions worldwide. However, epidemiologic data from Central and Eastern Europe are lacking. OBJECTIVES: This study aimed to assess the prevalence, clinical profiles, and liver fibrosis burden of MASLD and MetALD in a...

Topics

Join the communities discussing this publication.

• Aged
• Cohort Studies
• Liver Cirrhosis
• Metabolic Diseases
• Phenotype